LEXX
Lexaria Bioscience Corp.
Biotechnology
Market Cap$15M
5Y Perf.-85.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LEXX vs AVDL
Revenue, margins, valuation, and 5-year total return — side by side.
AVDL
Avadel Pharmaceuticals plc
Drug Manufacturers - Specialty & Generic
Market Cap$2.10B
5Y Perf.+195.2%
LEXX vs AVDL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LEXX | AVDL |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $15M | $2.10B |
| Revenue (TTM) | $522K | $249M |
| Net Income (TTM) | $-11M | $-278K |
| Gross Margin | 84.9% | 94.5% |
| Operating Margin | -20.2% | 1.8% |
| Forward P/E | — | 28.3x |
| Total Debt | $109K | $2M |
| Cash & Equiv. | $2M | $51M |
LEXX vs AVDL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LEXX
AVDL
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Lexaria Bioscience … (LEXX) | 100 | 14.6 | -85.4% |
| Avadel Pharmaceutic… (AVDL) | 100 | 295.2 | +195.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LEXX vs AVDL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AVDL leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
LEXX
Lexaria Bioscience Corp.
The Growth Angle
In this particular matchup, LEXX is outpaced on most metrics by others in the set.
Best for: healthcare exposure
AVDL
Avadel Pharmaceuticals plc
The Income Pick
AVDL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.23
- Rev growth 5.0%, EPS growth 74.5%
- 99.3% 10Y total return vs LEXX's -84.9%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AVDL | 5.0% revenue growth vs LEXX's 52.0% |
| Quality / Margins | AVDL | -0.1% margin vs LEXX's -20.7% |
| Stability / Safety | AVDL | Beta 0.23 vs LEXX's 1.00, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AVDL | +150.5% vs LEXX's -37.6% |
| Efficiency (ROA) | AVDL | -0.2% ROA vs LEXX's -178.4%, ROIC -76.3% vs -7.9% |
LEXX vs AVDL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
LEXX vs AVDL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAVDLLAGGINGLEXX
LEXXLexaria Bioscience Co…
0leads
AVDLAvadel Pharmaceutical…
5leads
6 Total Categories
CATEGORYLEADERvs LEXXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AVDL6/6
Valuation MetricsMultiples, price ratios, and targets
AVDL2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AVDL7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
AVDL5/6
Risk & VolatilityBeta, volatility, and downside exposure
AVDL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AVDL leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AVDL is the larger business by revenue, generating $249M annually — 476.1x LEXX's $522,000. AVDL is the more profitable business, keeping -0.1% of every revenue dollar as net income compared to LEXX's -20.7%. On growth, AVDL holds the edge at +54.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | LEXXLexaria Bioscienc… | AVDLAvadel Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $522,000 | $249M |
| EBITDAEarnings before interest/tax | -$10M | $8M |
| Net IncomeAfter-tax profit | -$11M | -$278,000 |
| Free Cash FlowCash after capex | -$9M | $35M |
| Gross MarginGross profit ÷ Revenue | +84.9% | +94.5% |
| Operating MarginEBIT ÷ Revenue | -20.2% | +1.8% |
| Net MarginNet income ÷ Revenue | -20.7% | -0.1% |
| FCF MarginFCF ÷ Revenue | -16.7% | +14.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +54.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +53.4% | +100.7% |
AVDL leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
AVDL leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | LEXXLexaria Bioscienc… | AVDLAvadel Pharmaceut… |
|---|---|---|
| Market CapShares × price | $15M | $2.1B |
| Enterprise ValueMkt cap + debt − cash | $13M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.02x | -42.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 28.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 21.23x | 12.44x |
| Price / BookPrice ÷ Book value/share | 4.66x | 27.88x |
| Price / FCFMarket cap ÷ FCF | — | — |
AVDL leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
AVDL leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
AVDL delivers a -0.3% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-2 for LEXX. AVDL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to LEXX's 0.04x. On the Piotroski fundamental quality scale (0–9), AVDL scores 4/9 vs LEXX's 3/9, reflecting mixed financial health.
| Metric | LEXXLexaria Bioscienc… | AVDLAvadel Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -0.3% |
| ROA (TTM)Return on assets | -178.4% | -0.2% |
| ROICReturn on invested capital | -7.9% | -76.3% |
| ROCEReturn on capital employed | -2.2% | -34.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.04x | 0.02x |
| Net DebtTotal debt minus cash | -$2M | -$50M |
| Cash & Equiv.Liquid assets | $2M | $51M |
| Total DebtShort + long-term debt | $109,320 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | 0.66x |
AVDL leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
AVDL leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVDL five years ago would be worth $27,462 today (with dividends reinvested), compared to $1,098 for LEXX. Over the past 12 months, AVDL leads with a +150.5% total return vs LEXX's -37.6%. The 3-year compound annual growth rate (CAGR) favors AVDL at 13.4% vs LEXX's -12.9% — a key indicator of consistent wealth creation.
| Metric | LEXXLexaria Bioscienc… | AVDLAvadel Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +3.1% | +0.6% |
| 1-Year ReturnPast 12 months | -37.6% | +150.5% |
| 3-Year ReturnCumulative with dividends | -33.9% | +45.8% |
| 5-Year ReturnCumulative with dividends | -89.0% | +174.6% |
| 10-Year ReturnCumulative with dividends | -84.9% | +99.3% |
| CAGR (3Y)Annualised 3-year return | -12.9% | +13.4% |
AVDL leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
AVDL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AVDL is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than LEXX's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVDL currently trades 91.8% from its 52-week high vs LEXX's 43.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LEXXLexaria Bioscienc… | AVDLAvadel Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 0.23x |
| 52-Week HighHighest price in past year | $1.55 | $23.57 |
| 52-Week LowLowest price in past year | $0.46 | $8.44 |
| % of 52W HighCurrent price vs 52-week peak | +43.5% | +91.8% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 179K | 0 |
AVDL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LEXXLexaria Bioscienc… | AVDLAvadel Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $22.50 |
| # AnalystsCovering analysts | — | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AVDL leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallAvadel Pharmaceuticals plc (AVDL)Leads 5 of 6 categories
Loading custom metrics...
LEXX vs AVDL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LEXX or AVDL a better buy right now?
For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.
8% revenue growth year-over-year, versus 52. 0% for Lexaria Bioscience Corp. (LEXX). Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LEXX or AVDL?
Over the past 5 years, Avadel Pharmaceuticals plc (AVDL) delivered a total return of +174.
6%, compared to -89. 0% for Lexaria Bioscience Corp. (LEXX). Over 10 years, the gap is even starker: AVDL returned +99. 3% versus LEXX's -84. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LEXX or AVDL?
By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.
23β versus Lexaria Bioscience Corp. 's 1. 00β — meaning LEXX is approximately 336% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 4% for Lexaria Bioscience Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — LEXX or AVDL?
By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.
8% versus 52. 0% for Lexaria Bioscience Corp. (LEXX). On earnings-per-share growth, the picture is similar: Avadel Pharmaceuticals plc grew EPS 74. 5% year-over-year, compared to -40. 4% for Lexaria Bioscience Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LEXX or AVDL?
Avadel Pharmaceuticals plc (AVDL) is the more profitable company, earning -28.
9% net margin versus -1686. 0% for Lexaria Bioscience Corp. — meaning it keeps -28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVDL leads at -25. 1% versus -1648. 0% for LEXX. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LEXX or AVDL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LEXX or AVDL better for a retirement portfolio?
For long-horizon retirement investors, Avadel Pharmaceuticals plc (AVDL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
23)). Both have compounded well over 10 years (AVDL: +99. 3%, LEXX: -84. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LEXX and AVDL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(LEXX: -100.0% · AVDL: 54.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.